D. Porter

发表

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

A. Bagg, D. Porter, B. Levine, 2011, The New England journal of medicine.

An inhibitor of eIF2 activity in the sRNA pool of eukaryotic cells.

D. Porter, M. Centrella, T. McCarthy, 2011, Gene.

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.

David L Porter, D. Teachey, S. Grupp, 2015, Blood.

Chimeric antigen receptor T cells for sustained remissions in leukemia.

Pamela A Shaw, Bruce L Levine, Yolanda D Mahnke, 2014, The New England journal of medicine.

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

David L. Porter, Adam Bagg, Wei-Ting Hwang, 2015, Science Translational Medicine.

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Robert H. Collins, R. Collins, J. Nemunaitis, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Peripheral-blood stem cells versus bone marrow from unrelated donors.

P. Westervelt, S. Mineishi, D. Porter, 2012, The New England journal of medicine.

Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas.

D. Porter, B. Levine, C. June, 2015 .

T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome.

J. Dipersio, D. Porter, S. Farag, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

First International Workshop on the Biology , Prevention and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation : Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

E. Estey, D. Porter, K. Peggs, 2010 .

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

E. Estey, D. Maloney, D. Porter, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

‘GVHD’: graft-versus-host disease or graft-versus-Hodgkin's disease? an old acronym with new meaning

D. Porter, H. Lazarus, E. Stadtmauer, 2003, Bone Marrow Transplantation.

The graft-versus-leukemia effects of allogeneic cell therapy.

D. Porter, J. Antin, 1999, Annual review of medicine.

High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation.

D. Porter, S. Schuster, S. Luger, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Acute myeloid leukaemia Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease

D. Porter, S. Schuster, S. Luger, 2002 .

Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation.

S. Grupp, D. Porter, B. Levine, 2003, Blood.

Cytokine release syndrome and neurotoxicity following CAR T therapy for hematologic malignancies.

D. Porter, Craig W. Freyer, 2020, The Journal of allergy and clinical immunology.

Advances in CAR T Therapy for Hematologic Malignancies

D. Porter, Craig W. Freyer, 2020, Pharmacotherapy.

Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells

S. Grupp, D. Porter, B. Levine, 2014 .

CAR T Toxicity Management: Cytokine Release Syndrome and Neurotoxicity

D. Porter, Craig W. Freyer, 2021 .

Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.

D. Teachey, S. Grupp, D. Porter, 2016, Journal of immunological methods.

Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

D. Porter, B. Levine, C. June, 2014 .

Circulating Osteogenic Precursor Cells in Heterotopic Bone Formation

Robin K Suda, D. Porter, P. Billings, 2009, Stem cells.

Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy.

D. Porter, N. Frey, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Dual CD 19 and CD 123 targeting prevents antigen-loss relapses after CD 19-directed immunotherapies

S. Grupp, D. Porter, M. Kalos, 2019 .

Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells.

M. Morgan, D. Porter, C. June, 2017, Journal of immunotherapy.

Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia.

D. Porter, N. Frey, 2016, Hematology. American Society of Hematology. Education Program.

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

J. Byrd, A. Johnson, Alexandria P. Cogdill, 2016, Blood.

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

S. Grupp, D. Porter, M. Kalos, 2016, The Journal of clinical investigation.

CAR T‐cells merge into the fast lane of cancer care

D. Porter, N. Frey, 2016, American journal of hematology.

Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells

S. Grupp, D. Porter, C. June, 2015, Journal of Immunotherapy for Cancer.

Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)

M. Bar, G. Mufti, S. Grupp, 2019, Bone Marrow Transplantation.

Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.

M. Bar, G. Mufti, S. Grupp, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc).

D. Teachey, S. Grupp, D. Porter, 2012 .

Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies

D. Porter, S. Goldstein, 2010, Expert review of hematology.

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

S. Grupp, D. Porter, B. Levine, 2013 .

T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL

D. Teachey, S. Grupp, D. Porter, 2014 .

Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers

M. Morgan, D. Porter, B. Levine, 2015 .

Post-transplant lymphoproliferative disorder: a review

D. Porter, A. Loren, E. Stadtmauer, 2003, Bone Marrow Transplantation.

National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.

N. Kröger, D. Porter, C. June, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL

D. Teachey, D. Porter, B. Levine, 2013 .

CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL.

J. Byrd, D. Porter, C. June, 2017 .

SP-024 CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS FOR RELAPSED,REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

D. Porter, B. Levine, C. June, 2014 .

Risk of invasive fungal infections in patients with high‐risk MDS and AML receiving hypomethylating agents

Shannon R. McCurdy, D. Porter, A. Perl, 2020, American journal of hematology.

Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program.

D. Porter, K. Ballen, D. Confer, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematopoietic stem cell transplantation: ASBMT/CIBMTR 2010 tandem meeting highlights and discussion†

D. Porter, N. Frey, 2010, American Journal of Hematology.

Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL).

S. Grupp, D. Porter, B. Levine, 2016 .

Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL

D. Teachey, S. Grupp, D. Porter, 2015 .

Acute cholecystitis is a common complication after allogeneic stem cell transplantation and is associated with the use of total parenteral nutrition.

D. Porter, S. Luger, E. Hexner, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Chimeric antigen receptor therapy for cancer.

David L Porter, S. Grupp, D. Porter, 2014, Annual review of medicine.

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Bernd Hauck, Bruce L Levine, David L Porter, 2013, The New England journal of medicine.

Donor leukocyte infusions in acute lymphocytic leukemia

R. Collins, A. Kirk, D. Porter, 2000, Bone Marrow Transplantation.

CAR T Cells for Hematologic Malignancies

D. Porter, Craig W. Freyer, 2021 .

Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic

P. Riedell, S. Grupp, M. Perales, 2020, Biology of Blood and Marrow Transplantation.

Cellular adoptive immunotherapy after autologous and allogeneic hematopoietic stem cell transplantation.

D. Porter, Jeffrey S. Miller, E. Hexner, 2009, Cancer treatment and research.

Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation

D. Porter, A. Loren, 2006, Current opinion in oncology.

Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation

D. Porter, S. Emerson, A. Perl, 2005, Bone Marrow Transplantation.

Cellular immune therapy for refractory cancers: novel therapeutic strategies.

P. Westervelt, D. Porter, P. Quesenberry, 2005, Experimental hematology.

Low Dose Total Body Irradiation Followed by Allogeneic Lymphocyte Infusion for Refractory Hematologic Malignancy—an Updated Review

D. Porter, P. Quesenberry, K. Ballen, 2004, Leukemia & lymphoma.

Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia.

D. Porter, B. Levine, C. June, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes.

M. Norkin, W. Wood, M. Sorror, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Relapse after allogeneic hematopoietic cell therapy.

R. Jenq, M. V. D. van den Brink, D. Porter, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.

S. Grupp, D. Porter, B. Levine, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cellular therapy following allogeneic stem-cell transplantation

D. Porter, A. Rager, Alison Rager, 2011, Therapeutic advances in hematology.

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

David L. Porter, Adam Bagg, Bruce L. Levine, 2011, Science Translational Medicine.

Allogeneic hematopoietic cell transplant for HIV patients with hematologic malignancies: the BMT CTN-0903/AMC-080 trial.

J. Mellors, D. Porter, M. Horowitz, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma.

D. Porter, S. Schuster, E. Stadtmauer, 2015, Clinical lymphoma, myeloma & leukemia.

ASH 2010 meeting report—Top 10 abstracts in hematopoietic stem cell transplantation

D. Porter, N. Frey, 2011 .

Post‐transplant outcomes of induction therapy for myeloma: Thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high‐dose melphalan with autologous stem cell support

D. Porter, E. Glatstein, S. Schuster, 2007, American journal of hematology.

Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome

H. Deeg, D. Porter, G. Gui, 2020, medRxiv.

Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most.

D. Porter, M. Horowitz, K. Hsu, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Somatic HLA Mutations Expose the Role of Class I-Mediated Autoimmunity in Aplastic Anemia and its Clonal Complications.

J. Biegel, D. Monos, T. Olson, 2017, Blood advances.

Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancer.

M. Morgan, D. Porter, P. O'Neil, 1997, Gynecologic oncology.

Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas.

D. Torigian, D. Porter, C. June, 2018, Cytotherapy.

Autologous stem cell transplantation in first complete remission may not extend progression‐free survival in patients with peripheral T cell lymphomas

D. Porter, S. Schuster, A. Mato, 2016, American journal of hematology.

transplantation with unrelated donor leukocyte infusions Treatment of relapsed leukemia after unrelated donor marrow

D. Porter, R. Mick, J. Antin, 2013 .

Umbilical cord blood transplantation: where do we stand?

D. Porter, R. C. Wadlow, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

mpact of Donor and Recipient Sex and Parity n Outcomes of HLA-Identical Sibling Allogeneic ematopoietic Stem Cell Transplantation

D. Porter, A. Cnaan, M. Horowitz, 2006 .

Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion.

D. Porter, J. Levine, 2006, Seminars in hematology.

Cutaneous Hodgkin's disease.

D. Porter, J. Kantor, J. Junkins-Hopkins, 2008, Journal of the American Academy of Dermatology.

Risk Factors for Venous Thromboembolism In Hospitalized Cancer Patients with Central Catheters

S. Trerotola, D. Porter, E. Scott, 2010 .

Donor leukocyte infusions for multiple myeloma

R. Collins, A. Kirk, D. Porter, 2000, Bone Marrow Transplantation.

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma

D. Porter, S. Schuster, S. Luger, 2009, Bone Marrow Transplantation.

Lenalidomide and stem cell collection in patients with multiple myeloma

D. Porter, S. Luger, E. Stadtmauer, 2008 .

Association of HLA Polymorphisms with Post‐transplant Lymphoproliferative Disorder in Solid‐Organ Transplant Recipients

D. Heitjan, D. Porter, J. Tomaszewski, 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment

D. Porter, B. Levine, C. June, 2016, American journal of hematology.

Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation.

D. Porter, B. Levine, C. June, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

M. Bar, G. Mufti, S. Grupp, 2021 .

Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.

E. Leifer, N. Geller, D. Porter, 2021, Transplantation and cellular therapy.

Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation.

T. Braun, R. Collins, K. Cornetta, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.

D. Porter, J. Ferrara, J. Antin, 1994, The New England journal of medicine.

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia

Shannon R. McCurdy, M. Carroll, D. Porter, 2022, Blood advances.

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

R. Vij, M. Perales, F. Appelbaum, 2015, Blood.

Larger Numbers of Donor Naïve CD8+ T-Cells and Plasmacytoid Dendritic Cell Precursors In Allogeneic BM Grafts From Unrelated Donors Are Associated with Improved Survival: Results From BMT CTN 0201

Cathy Gurgol, S. Mineishi, D. Porter, 2011 .

Graft-versus-host disease after donor leukocyte infusions: presentation and management.

D. Porter, N. Frey, 2008, Best practice & research. Clinical haematology.

Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation

D. Porter, A. Loren, 2008, Bone Marrow Transplantation.

Donor leukocyte infusions in myeloid malignancies: new strategies.

D. Porter, J. Antin, 2006, Best practice & research. Clinical haematology.

Donor leukocyte infusions in acute myelogenous leukemia

D. Porter, 2003, Leukemia.

Infusion of donor peripheral blood mononuclear cells to treat relapse after transplantation for chronic myelogenous leukemia.

D. Porter, J. Antin, David L Porter, 1998, Hematology/oncology clinics of North America.

Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia

S. Grupp, D. Porter, B. Levine, 2016 .

Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.

D. Teachey, S. Grupp, D. Porter, 2016 .

Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation

D. Porter, R. Elstrom, E. Glatstein, 2005, Leukemia & lymphoma.

Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia

Amanda M Li, D. Teachey, A. Seif, 2018, Blood.

Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

S. Grupp, D. Porter, P. Wood, 2018, Journal of Hematology & Oncology.

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Amanda M Li, D. Teachey, S. Grupp, 2017 .

Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease.

D. Porter, H. Hosoya, D. Henry, 2018, Blood advances.

Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-cell Lymphomas.

P. Riedell, M. Perales, D. Porter, 2022, Transplantation and cellular therapy.

Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting.

D. Porter, S. Schuster, M. Ruella, 2022, Clinical lymphoma, myeloma & leukemia.

Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation.

M. Carroll, D. Porter, S. Luger, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical Utility of Next Generation Sequencing for Oncogenic Mutations in AML Patients Undergoing Allogeneic Stem Cell Transplantation Biol Blood Marrow

M. Carroll, D. Porter, Selina, 2016 .

Trisomy 8 in an allogeneic stem cell transplant recipient representative of a donor‐derived constitutional abnormality

P. Nowell, D. Porter, S. Luger, 2008, American journal of hematology.

D. Porter, S. Luger, E. Hexner, 2016, American journal of hematology.

Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma

P. Gimotty, D. Porter, R. Elstrom, 2005, Bone Marrow Transplantation.

Granulocytic sarcoma: an atypical presentation in the oral cavity.

D. Porter, F. Alawi, T. Sollecito, 2004, Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry.

Leukemic gingival infiltrate as an indicator of chemotherapeutic failure following monoclonal antibody therapy: a case report.

D. Porter, S. Schuster, T. Sollecito, 2003, Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry.

APhase I Study of Bexarotene, a Retinoic X ReceptorAgonist, in Non-M3 AcuteMyeloid Leukemia

A. Bagg, D. Porter, S. Schuster, 2008 .

Study of Bexarotene , a Retinoic X ReceptorAgonist , in Non-M 3 AcuteMyeloid Leukemia

A. Bagg, D. Porter, S. Schuster, 2008 .

A phase I trial of bexarotene, a retinoid X receptor agonist, in non-M3 acute myeloid leukemia

M. Carroll, D. Porter, C. Andreadis, 2007 .

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.

E. Leifer, N. Geller, H. Deeg, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium.

D. Porter, F. Locatelli, E. Holler, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Homocysteine and prothrombin fragment 1+2 levels in patients with veno-occlusive disease after stem cell transplantation.

D. Porter, R. Mick, K. High, 2003, Journal of hematotherapy & stem cell research.

Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens

D. Porter, A. Perl, S. Luger, 2013, American journal of hematology.

Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation.

D. Porter, J. Ferrara, J. Antin, 1996, Bone marrow transplantation.

Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia

Shannon R. McCurdy, D. Porter, K. Pratz, 2022, Leukemia & lymphoma.

Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene

P. Nowell, M. Carroll, A. Bagg, 2007, Cancer biology & therapy.

Allogeneic hematopoietic stem cell transplantation for primary cutaneous T cell lymphomas

D. Porter, Ellen J. Kim, A. Rook, 2011, Bone Marrow Transplantation.

Reduced‐dose fludarabine, cyclophosphamide, and rituximab (FCR‐Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia

D. Porter, K. Foon, S. Schuster, 2015, American journal of hematology.

Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis

S. Galetta, N. Volpe, D. Porter, 2008, Journal of the Neurological Sciences.

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015).

S. Grupp, J. Gartner, S. Rosenberg, 2015, Journal for immunotherapy of cancer.

Inflammatory Cytokine Inhibition with Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease

D. Porter, A. Perl, S. Luger, 2010, Bone Marrow Transplantation.

Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors.

D. Porter, S. Luger, E. Hexner, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Higher Donor Apheresis Blood Volumes Are Associated with a Reduction in Relapse Risk and Improved Survival in Reduced Intensity Allogeneic Transplants with Unrelated Donors

D. Porter, S. Luger, E. Hexner, 2018 .

High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.

D. Porter, R. Mick, T. Kambayashi, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.

J. Hoxie, D. Porter, E. Acosta, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia

D. Porter, C. June, M. Klichinsky, 2015 .

Low dose total body irradiation added to fludarabine and busulfan reduced intensity conditioning reduces graft failure in patients with myelofibrosis.

D. Porter, A. Maity, J. Plastaras, 2022, Transplantation and cellular therapy.

Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.

A. Alavi, D. Porter, D. Goldenberg, 2003, Clinical lymphoma.

Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma.

D. Porter, S. Schuster, A. Perl, 2015, Clinical lymphoma, myeloma & leukemia.

The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL).

D. Teachey, A. Seif, S. Grupp, 2017 .

allogeneic stem cell transplantation for refractory Hodgkin ’ s lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy

D. Porter, R. Buckanovich, A. Pruitt, 2022 .

Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia.

D. Porter, C. Nabhan, S. Schuster, 2016, Blood.

Clofarabine and busulfan myeloablative conditioning in allogeneic hematopoietic cell transplant for patients with active myeloid malignancies.

Shannon R. McCurdy, D. Porter, K. Pratz, 2022, Transplantation and cellular therapy.

Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901

E. Leifer, N. Geller, H. Deeg, 2015 .

Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post‐transplant lymphoproliferative disorder *

D. Porter, K. Olthoff, R. Bloom, 2005, Clinical transplantation.

Use of EBV PCR for the Diagnosis and Monitoring of Post‐Transplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Patients

D. Porter, K. Olthoff, R. Kotloff, 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Treatment of Acute Graft-vs-Host Disease

D. Porter, S. Goldstein, S. Stein, 2010 .

Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation

D. Porter, W. Hwang, T. Miano, 2016, Bone Marrow Transplantation.

Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination

D. Porter, R. Mick, L. Schuchter, 1999, Medical oncology.

Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients.

D. Porter, D. Babushok, S. Luger, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

D. Porter, J. Leis, 2002, Leukemia & lymphoma.

Graft-versus-leukemia effect of allogeneic bone marrow transplantation and donor mononuclear cell infusions.

D. Porter, J. Antin, 1997, Cancer treatment and research.

Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.

D. Porter, L. Schuchter, A. Cesano, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

ASH 2009 meeting report—Top 10 clinically‐oriented abstracts in hematopoietic stem cell transplantation

D. Porter, 2010 .

Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay.

Shannon R. McCurdy, D. Porter, D. Babushok, 2021, Transplantation and cellular therapy.

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.

S. Grupp, D. Porter, M. Pasquini, 2014, Blood.

Combined autophagy and proteasome inhibition

J. Bradner, D. Heitjan, D. Porter, 2014, Autophagy.

Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies.

J. Connors, D. Porter, S. Saidman, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population

R. Collins, D. Porter, A. Barrett, 2008, Bone Marrow Transplantation.

Donor mononuclear cell infusions as therapy for B-cell lymphoproliferative disorder following allogeneic bone marrow transplant.

D. Porter, J. Antin, G. Orloff, 1994, Transplantation science.

Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)

D. Teachey, S. Grupp, D. Porter, 2015 .

Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T‐cell acute lymphoblastic leukaemia and lymphoma

D. Porter, S. Luger, N. Frey, 2016, British journal of haematology.

Adoptive immunotherapy for relapsed leukemia following allogeneic bone marrow transplantation.

D. Porter, J. Antin, 1995, Leukemia & lymphoma.

Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells

D. Porter, C. June, J. Melenhorst, 2017 .

Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402

S. Grupp, D. Porter, M. Pasquini, 2012 .

Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials.

M. Perales, F. Appelbaum, D. Porter, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder ★

D. Heitjan, D. Porter, L. Goldberg, 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies

D. Teachey, S. Grupp, D. Porter, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder

D. Heitjan, A. Bagg, D. Porter, 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients

B. Cheson, D. Porter, C. Nabhan, 2016 .

Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Sadik H. Kassim, E. Wherry, F. Johnson, 2021, Nature medicine.

Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate

J. Byrd, D. Porter, C. June, 2018, Blood.

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduce

N. Geller, P. Hari, D. Porter, 2019, The Lancet. Haematology.

Antibody-modified T cells: CARs take the front seat for hematologic malignancies.

Marcela V Maus, David L Porter, S. Grupp, 2014, Blood.

Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

Gregory M. Chen, F. Bushman, E. Wherry, 2022, Nature.

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

R. Vij, M. Perales, F. Appelbaum, 2015, Blood.

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.

H. Deeg, D. Porter, G. Gui, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.

D. Porter, M. Wasik, W. Blonski, 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment and Length of Hospitalization in Myeloablative Allogeneic Hematopoietic Transplantation

Shannon R. McCurdy, D. Porter, D. Babushok, 2019, Biology of Blood and Marrow Transplantation.

Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis in Myeloablative Allogeneic Hematopoietic Transplantation Shortens the Duration of Mucositis and Hospitalization

Shannon R. McCurdy, D. Porter, D. Babushok, 2018, Blood.

Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas

Stephen J. Schuster, David L. Porter, Jakub Svoboda, 2017, The New England journal of medicine.

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.

M. Carroll, S. Grupp, D. Porter, 2014, Blood.

A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs.

D. Porter, A. Mato, 2015, Blood.

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Hans Bitter, Wei-Ting Hwang, Iulian Pruteanu-Malinici, 2018, Nature Medicine.

Current concepts in the diagnosis and management of cytokine release syndrome.

S. Grupp, D. Porter, C. Mackall, 2014, Blood.

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Tyler J. Reich, F. Bushman, S. Carty, 2018, Nature.

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer

W. Blackwelder, D. Porter, B. Levine, 2005, Nature Medicine.

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

M. Dhodapkar, S. Grupp, D. Maloney, 2018, Journal of Immunotherapy for Cancer.

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia

M. Carroll, D. Porter, C. June, 2015, Leukemia.

Chimeric antigen receptor T cell therapy: 25years in the making.

D. Porter, M. Maus, S. Gill, 2016, Blood reviews.

CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration.

F. Bushman, S. Grupp, D. Porter, 2019, The Journal of clinical investigation.

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

G. Wertheim, D. Teachey, S. Grupp, 2016, Cancer discovery.

Reduced-intensity hematopoietic stem cell transplants for malignancies: harnessing the graft-versus-tumor effect.

D. Porter, S. Gill, 2013, Annual review of medicine.

Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.

D. Porter, 2011, Hematology. American Society of Hematology. Education Program.

CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road

D. Porter, S. Gill, 2014, Expert opinion on biological therapy.

Acute myelogenous leukemia: advances and limitations of treatment.

Thomas P Sollecito, D. Porter, S. Schuster, 2002, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation

Shannon R. McCurdy, D. Porter, K. Pratz, 2020, Leukemia & lymphoma.

Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia

D. Teachey, S. Grupp, D. Porter, 2017, Critical care medicine.

Evolution to plasmablastic lymphoma evades CD19‐directed chimeric antigen receptor T cells

J. Friedberg, D. Porter, P. Rothberg, 2015, British journal of haematology.

Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide

Shannon R. McCurdy, D. Porter, K. Pratz, 2022, Leukemia & lymphoma.

Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse.

D. Porter, S. Gill, S. Kenderian, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

State-of-the-Art Review The Graft-versus-Tumor Potential of Allogeneic Cell Therapy: An Update on Donor Leukocyte Infusions and Nonmyeloablative Allogeneic Stem Cell Transplantation

D. Porter, 2001 .

The graft-versus-tumor potential of allogeneic cell therapy: an update on donor leukocyte infusions and nonmyeloablative allogeneic stem cell transplantation.

D. Porter, 2001, Journal of hematotherapy & stem cell research.

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.

D. Porter, D. Leonard, S. Schuster, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

transplantation with unrelated donor leukocyte infusions Treatment of relapsed leukemia after unrelated donor marrow

R. Collins, D. Porter, R. Mick, 2013 .

Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions.

J. Connors, R. Collins, D. Porter, 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

ex-vivo via CD3/CD28 co-stimulation A phase I trial of donor lymphocyte infusions expanded and activated

D. Porter, B. Levine, S. Emerson, 2012 .

A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.

Alexander Perl, Bruce L Levine, David L Porter, 2006, Blood.

A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD 3 / CD 28 costimulation

D. Porter, B. Levine, C. June, 2006 .

A predictive model for the detection of tumor lysis syndrome during AML induction therapy

D. Heitjan, M. Carroll, D. Porter, 2006, Leukemia & lymphoma.

Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signature.

D. Porter, C. Pasin, A. Yates, 2021, Transplantation and cellular therapy.

Graft-versus-host disease depletes plasmacytoid dendritic cell progenitors to impair tolerance induction.

S. Mineishi, D. Porter, Yanyun Zhang, 2020, The Journal of clinical investigation.

Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Y. Taur, E. Pamer, M. Perales, 2022, Nature Medicine.

BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.

Tyler J. Reich, Christopher J. Ott, F. Bushman, 2021, The Journal of clinical investigation.

The promise of chimeric antigen receptor T cells (CARTs) in leukaemia

D. Porter, N. Frey, R. Orlowski, 2017, British journal of haematology.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

J. Friedberg, M. Shipp, P. L. Bergsagel, 2016, Journal of Immunotherapy for Cancer.

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

S. Grupp, D. Porter, P. Wood, 2018, Journal of Hematology & Oncology.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma

J. Friedberg, S. Ansell, D. Porter, 2020, Journal for ImmunoTherapy of Cancer.

Immunotherapy with cells.

D. Porter, E. Chong, 2020, Hematology. American Society of Hematology. Education Program.

UNDERSTANDING HOW TO MANIPULATE THE IMMUNE SYSTEM IN IMMUNOTHERAPY FOR LYMPHOMA Immunotherapy with cells

D. Porter, E. Chong, 2020 .

Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.

S. Grupp, D. Porter, B. Levine, 2017, Blood.

CCR5-edited CD4 T cells augment HIV-specific immunity to enable post rebound control of HIV replication.

D. Porter, B. Levine, C. June, 2021, The Journal of clinical investigation.

T-cell reconstitution and expansion after hematopoietic stem cell transplantation: ‘T’ it up!

D. Porter, C. June, 2005, Bone Marrow Transplantation.

Series ACUTE LYMPHOBLASTIC LEUKEMIA CD 19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

David L. Porter, D. Teachey, S. Grupp, 2016 .

Anti-CD123 Chimeric Antigen Receptor T Cells (CART-123) Provide A Novel Myeloablative Conditioning Regimen That Eradicates Human Acute Myeloid Leukemia In Preclinical Models

M. Carroll, S. Grupp, D. Porter, 2013 .

A Phase I Study Using Single Agent Birinapant in Patients with Relapsed Myelodysplastic Syndrome and Acute Myelogenous Leukemia

M. Carroll, D. Porter, H. Minderman, 2014 .

Title : Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia

G. Wertheim, D. Teachey, S. Grupp, 2016 .

Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy.

L. Solin, K. Fox, D. Porter, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Do simultaneous bilateral tunneled infusion catheters in patients undergoing bone marrow transplantation increase catheter-related complications?

D. Roberts, S. Stavropoulos, J. Mondschein, 2004, Journal of vascular and interventional radiology : JVIR.

Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis.

J. Hoxie, D. Porter, R. H. Moy, 2017, Blood.

Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen

D. Porter, A. Nazha, S. Schuster, 2011, Bone Marrow Transplantation.

High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT

D. Heitjan, D. Porter, S. Luger, 2012, Bone Marrow Transplantation.

Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation.

D. Porter, A. Cnaan, M. Horowitz, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prospective T rial o f C hemotherapy a nd D onor L eukocyte Infusions f or R elapse o f A dvanced M yeloid M alignancies After A llogeneic S tem-Cell T ransplantation

T. Braun, K. Cornetta, D. Porter, 2002 .

Prevention and treatment of relapse after stem cell transplantation by cellular therapies

N. Kröger, M. Mohty, D. Porter, 2018, Bone Marrow Transplantation.

Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients.

D. Porter, T. Miano, R. Vonderheide, 2015, The Journal of antimicrobial chemotherapy.

Tocilizumab Is Highly Active for Severe Steroid-Refractory Acute Graft-Versus-Host Disease of the Gastrointestinal Tract

D. Porter, D. Babushok, S. Luger, 2016 .

Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

D. Porter, M. Horowitz, R. Soiffer, 2011, Blood.

Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation.

D. Porter, M. Wasik, R. Mick, 2000, Journal of hematotherapy & stem cell research.

Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.

J. Ritz, P. Westervelt, J. Dipersio, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

J. Hoxie, D. Heitjan, D. Porter, 2012, The New England journal of medicine.

Reduced-intensity conditioned allogeneic SCT in adults with AML

D. Porter, R. Reshef, David L Porter, 2015, Bone Marrow Transplantation.

Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201.

S. Mineishi, D. Porter, T. Spitzer, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multicenter Retrospective Analysis of Outcomes and Toxicities with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

P. Riedell, M. Perales, D. Porter, 2020 .

Long-term Survival and Late Effects among 1-year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes

Zhiwei, Saber, M. Norkin, 2014 .

Erythropoietic protoporphyria in an adult with sequential liver and hematopoietic stem cell transplantation: A case report

E. Furth, D. Porter, K. Olthoff, 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning.

D. Porter, R. Mick, V. V. Van Deerlin, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia

Shannon R. McCurdy, D. Porter, K. Pratz, 2021, Blood.

Advances in CAR T-cell therapy for chronic lymphocytic leukemia.

D. Porter, 2018, Clinical advances in hematology & oncology : H&O.

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.

B. Cheson, D. Porter, A. Evens, 2016, Blood.

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Sadik H. Kassim, E. Wherry, H. Bitter, 2018, Nature Medicine.

Functional Unresponsiveness and Replicative Senescence of Myeloid Leukemia Antigen–specific CD8+ T Cells After Allogeneic Stem Cell Transplantation

F. Johnson, D. Porter, R. Vonderheide, 2009, Clinical Cancer Research.

Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia

J. Byrd, D. Porter, B. Levine, 2022, Blood advances.

Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy.

D. Porter, C. June, J. Melenhorst, 2018, Blood.

Decade-long remissions of leukemia sustained by the persistence of activated CD4+ CAR T-cells

Gregory M. Chen, F. Bushman, E. Wherry, 2021, bioRxiv.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation.

N. Kröger, D. Porter, M. Bishop, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The cytological features of CAR(T) cells

A. Bagg, D. Porter, C. June, 2016, British journal of haematology.

Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract

D. Porter, D. Babushok, S. Luger, 2019, Bone Marrow Transplantation.

Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

N. Kröger, D. Porter, C. June, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Novel approaches to allogeneic stem cell therapy

D. Porter, Vinona Bhatia, 2001, Expert opinion on biological therapy.

Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T‐cell therapy for chronic lymphocytic leukemia

D. Porter, S. Bair, 2019, American journal of hematology.

Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study

B. Cheson, D. Porter, A. Evens, 2015 .

Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma.

S. Grupp, D. Porter, B. Levine, 2018, Blood.

Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies

D. Porter, P. Dreger, M. Bishop, 2018, Bone Marrow Transplantation.

Engineered T cells for cancer therapy

S. Grupp, D. Porter, B. Levine, 2014, Cancer Immunology, Immunotherapy.

Transmission of an expanding donor-derived del(20q) clone through allogeneic hematopoietic stem cell transplantation without the development of a hematologic neoplasm.

A. Bagg, D. Porter, J. Morrissette, 2015, Cancer genetics.

Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.

K. Mansfield, D. Porter, C. June, 2017, Blood.

A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy

D. Porter, A. Maity, J. Plastaras, 2019, Blood.

A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

P. Riedell, M. Perales, D. Porter, 2019, Blood.

Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL.

S. Grupp, D. Porter, B. Levine, 2016 .

Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.

G. Wertheim, A. Bagg, D. Porter, 2016, Blood.

Innovation and Access at the Mercy of Payment Policy: The Future of Chimeric Antigen Receptor Therapies.

D. Porter, J. Bekelman, Christopher R. Manz, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience

D. Porter, S. Schuster, M. Ruella, 2019, Blood.

Anti-CD19 CAR-T for Treatment of Double Expressor and Double Hit Large B-Cell Lymphomas: A Single Institution Real-World Analysis

D. Porter, S. Schuster, M. Ruella, 2020 .

Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist – Final Results of a Phase I/II Study

J. Hoxie, D. Heitjan, D. Porter, 2011 .

D. Porter, S. Luger, E. Hexner, 2016, American journal of hematology.

Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL.

D. Teachey, S. Grupp, D. Porter, 2016 .

Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL

S. Grupp, D. Porter, B. Levine, 2012 .

The Promise of Chimeric Antigen Receptor T-Cell Therapy.

D. Porter, N. Frey, 2016, Oncology.

Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

D. Porter, B. Levine, C. June, 2015 .

malignancies Antibody-modified T cells: CARs take the front seat for hematologic

S. Grupp, D. Porter, C. June, 2014 .

Series ANTIBODY DERIVATIVES AS NEW THERAPEUTICS FOR HEMATOLOGIC MALIGNANCIES Antibody-modi fi ed T cells : CARs take the front seat for hematologic malignancies

S. Grupp, D. Porter, C. June, 2014 .

Chimeric Antigen Receptor Therapy for B-cell Malignancies

D. Porter, B. Levine, M. Kalos, 2011, Journal of Cancer.

modified T cells - myeloablation using chimeric antigen receptor Preclinical targeting of human acute myeloid leukemia and

M. Carroll, S. Grupp, D. Porter, 2014 .

myeloablation using chimeric antigen receptor Preclinical targeting of human acute myeloid leukemia

M. Carroll, S. Grupp, D. Porter, 2014 .

Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

S. Grupp, D. Porter, B. Levine, 2020 .

Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children.

Jason W. Moore, D. Teachey, S. Grupp, 2020, Blood advances.

Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis.

D. Porter, R. Vonderheide, R. Reshef, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

REDUCTION IN IMMUNOSUPPRESSION AS INITIAL THERAPY FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER: ANALYSIS OF PROGNOSTIC VARIABLES AND LONG-TERM FOLLOW-UP OF 42 ADULT PATIENTS1

B. Somer, D. Porter, R. Kotloff, 2001, Transplantation.

Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.

D. Porter, B. Levine, C. June, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia.

H. Deeg, D. Porter, J. Cortes, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant

Shannon R. McCurdy, D. Porter, K. Pratz, 2022, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia

M. Carroll, A. Bagg, D. Porter, 2008, Clinical Cancer Research.

Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation

A. Alavi, D. Porter, R. Elstrom, 2006, Bone Marrow Transplantation.

Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program.

B. Sandmaier, D. Porter, K. Ballen, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Extended Course of Maraviroc, a CCR5 Antagonist, Is Safe and Effective in Graft-Versus-Host Disease Prophylaxis. Final Results of a Phase II Study

J. Hoxie, D. Porter, E. Acosta, 2017 .

Novel treatments for chronic lymphocytic leukemia and moving forward.

D. Porter, S. O'brien, Jennifer R. Brown, 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia

M. Carroll, A. Bagg, D. Porter, 2009, Clinical Cancer Research.

Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8+ T Cells and Impede CAR T Cell Efficacy

D. Porter, C. June, J. Melenhorst, 2018, Blood.

CAR T cell viability release testing and clinical outcomes: is there a lower limit?

S. Grupp, D. Porter, B. Levine, 2019, Blood.

Evolution to Plasmablastic Lymphoma (PBL) after CAR-T Cell Therapy in a Case of SLL/CLL with Richter’s Transformation

D. Porter, P. Rothberg, J. Liesveld, 2014 .

Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas

D. Porter, S. Schuster, M. Ruella, 2019, Blood.

Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma.

D. Porter, R. Richards, A. Deol, 2022, Future oncology.

Implementation of an Advanced Practice Provider Service on an Allogeneic Stem Cell Transplant Unit: Impact on Patient Outcomes.

D. Porter, N. Mitra, M. Schapira, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma

D. Porter, B. Levine, C. June, 2016 .

Effective targeting of primary human acute myeloid leukemia using anti-CD123 chimeric antigen receptor engineered T cells

M. Carroll, S. Grupp, D. Porter, 2013 .

Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia

E. Wherry, F. Johnson, H. Bitter, 2017 .

Chronic myelogenous leukemia: extending the prospects for cure.

D. Porter, C. Mathias, A. Wakoff, 1998, Hospital practice.

Update: Meta-analysis of Overall Risk for Lymphoma with Immunomodulators for Inflammatory Bowel Disease: 1167

C. Brensinger, J. Lewis, D. Porter, 2010 .

Meta-analysis of risk for lymphoma with immunomodulators for inflammatory bowel disease.

C. Brensinger, J. Lewis, D. Porter, 2010 .

Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy.

Yong Gu Lee, F. Costabile, D. Porter, 2023, Molecular therapy : the journal of the American Society of Gene Therapy.

Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy

D. Porter, W. Hwang, S. Schuster, 2022, Blood.

Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma

P. Riedell, M. Perales, D. Porter, 2023, Transplantation and cellular therapy.

CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia

S. Grupp, D. Porter, B. Levine, 2018, Blood.

Continued observation and the collection of more data will be required to better define the relationship between skin lesions and CAR T-cell therapies

D. Porter, C. June, J. Melenhorst, 2016 .

Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy.

D. Porter, C. June, J. Melenhorst, 2016, Journal of the American Academy of Dermatology.

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy

D. Porter, B. Levine, C. June, 2016 .

The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies

Y. Taur, E. Pamer, M. Perales, 2021, Blood.

Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

D. Teachey, S. Grupp, D. Porter, 2015 .

Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies

S. Grupp, D. Porter, C. June, 2015 .

S1133 Hepatosplenic T-Cell Lymphoma (HSTCL) and Inflammatory Bowel Disease (IBD): A Rare Complication After Long-Term Thiopurine Exposure: Case Report and Systematic Review of the Literature

D. Porter, W. Blonski, M. Mendizabal, 2009 .

Voriconazole‐induced periostitis after allogeneic stem cell transplantation

D. Porter, N. Frey, B. Birnbaum, 2015, American journal of hematology.

Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction.

F. Bushman, S. Berger, D. Porter, 2023, Cancer discovery.

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

P. Riedell, M. Perales, D. Porter, 2022, Blood advances.

Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer.

M. Morgan, D. Porter, C. June, 2016 .

Real‐world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia

Shannon R. McCurdy, M. Carroll, D. Porter, 2023, American journal of hematology.

Plerixafor and G-CSF Versus Cyclophosphamide and G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma.

D. Porter, A. Nazha, S. Schuster, 2009 .

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

S. Grupp, D. Porter, C. June, 2017 .

A phase II, dose-optimization trial of autologous T cells genetically engineered to express anti-CD19 chimeric antigen receptor (CART-19) in patients with relapsed or refractory (r/r) CD19+ chronic lymphocytic leukemia (CLL).

D. Porter, B. Levine, M. Kalos, 2013 .

Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions.

R. Collins, D. Porter, R. Mick, 2000, Blood.

Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality

Laura Leary, D. Porter, H. Tun, 2018, Blood.

Survival outcomes for patients with relapsed/refractory aggressive B cell lymphomas following receipt of high dose chemotherapy/autologous stem transplantation and/or chimeric antigen receptor-modified T cells.

D. Porter, S. Schuster, S. Barta, 2023, Transplantation and cellular therapy.

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.

M. Carroll, S. Grupp, D. Porter, 2014, Blood.

A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)

J. Ritz, P. Westervelt, J. Dipersio, 2016 .

Venous Thromboembolism Following Pegaspargase in Adults Receiving Antithrombin Supplementation: A Single Center Characterization of Risk Factors and an Assessment of Supplementation Practice

Shannon R. McCurdy, D. Porter, A. Perl, 2018, Blood.

Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance

J. McQuade, D. Porter, S. Schuster, 2012, Bone Marrow Transplantation.

CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL

Shannon R. McCurdy, D. Porter, B. Levine, 2021, Blood.

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL

D. Teachey, S. Grupp, D. Porter, 2014 .

Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.

S. Grupp, D. Porter, B. Levine, 2017, Blood.

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Tyler J. Reich, F. Bushman, S. Carty, 2018, Nature.

Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T‐cell therapy for chronic lymphocytic leukemia

D. Porter, S. Bair, 2019, American journal of hematology.

Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.

K. Mansfield, D. Porter, C. June, 2017, Blood.

A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs.

D. Porter, A. Mato, 2015, Blood.

Peripheral-blood stem cells versus bone marrow from unrelated donors.

P. Westervelt, S. Mineishi, D. Porter, 2012, The New England journal of medicine.

Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis.

J. Hoxie, D. Porter, R. H. Moy, 2017, Blood.

Risk of Invasive Fungal Infections in Patients with High-Risk MDS and AML Receiving Hypomethylating Agents

Shannon R. McCurdy, D. Porter, A. Perl, 2018, Blood.

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

R. Vij, M. Perales, F. Appelbaum, 2015, Blood.

Survival after T-Cell Replete Haplo-Identical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor Transplant for Acute Myeloid Leukemia

R. Vij, M. Perales, F. Appelbaum, 2014 .

Current concepts in the diagnosis and management of cytokine release syndrome.

S. Grupp, D. Porter, C. Mackall, 2014, Blood.

Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium

P. Riedell, M. Gonen, M. Perales, 2022, Blood.

Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Y. Taur, E. Pamer, M. Perales, 2022, Nature Medicine.

Bendamustine Is a Safe and Effective Regimen for Lymphodepletion before Tisagenlecleucel in Patients with Large B-Cell Lymphomas

U. Jaeger, D. Porter, S. Schuster, 2021, Blood.

Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

D. Porter, M. Horowitz, R. Soiffer, 2011, Blood.

High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.

D. Porter, R. Mick, T. Kambayashi, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help

D. Maloney, D. Porter, S. Nikiforow, 2023, Blood advances.

Salvage therapy with basiliximab and etanercept for severe steroid‐refractory acute graft‐versus‐host disease

D. Porter, E. Hexner, A. Loren, 2022, American journal of hematology.

Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

D. Teachey, S. Grupp, D. Porter, 2016 .

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

P. Riedell, M. Gonen, M. Perales, 2023, Blood advances.

One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplant

D. Porter, D. Babushok, S. Luger, 2023, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia.

D. Porter, C. Nabhan, S. Schuster, 2016, Blood.

A Phase I Dose Escalation Study of the mTOR Inhibitor Sirolimus and MEC Chemotherapy Targeting Signal Transduction in Leukemic Stem Cells for Acute Myeloid Leukemia.

M. Carroll, D. Porter, S. Emerson, 2006 .

Pentosan polysulfate for the treatment of hemorrhagic cystitis after allogeneic hematopoietic cell transplant

Shannon R. McCurdy, D. Porter, S. Luger, 2022, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing

Shannon R. McCurdy, D. Porter, A. Perl, 2018, Blood.

Effect of Pharmacokinetic Variability on the Toxicity and Efficacy of High-Dose Melphalan for Multiple Myeloma

D. Porter, E. Stoopler, S. Luger, 2010 .